SMO-话题@MedSci

#SMO#

285篇内容 | 3665人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2024843, encodeId=5a67202484331, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO-WCGI大会主席说：肿瘤患者的抗凝治疗不应忽视, objectType=article, longId=175118, objectId=69fd1e5118fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69fd1e5118fd, replyNumber=0, likeNumber=74, createdTime=2020-05-19, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69fd1e5118fd, moduleTitle=ESMO-WCGI大会主席说：肿瘤患者的抗凝治疗不应忽视, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69fd1e5118fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024839, encodeId=2bdc20248399b, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, objectType=article, longId=174985, objectId=0a901e49851b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a901e49851b, replyNumber=0, likeNumber=74, createdTime=2019-10-19, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a901e49851b, moduleTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a901e49851b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024838, encodeId=06dd202483835, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新, objectType=article, longId=168877, objectId=2c901688e7bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c901688e7bc, replyNumber=0, likeNumber=44, createdTime=2020-05-20, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c901688e7bc, moduleTitle=ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c901688e7bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024860, encodeId=ede62024860d6, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, objectType=article, longId=180569, objectId=13a6180569e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a6180569e0, replyNumber=0, likeNumber=72, createdTime=2020-02-18, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a6180569e0, moduleTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a6180569e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024868, encodeId=ae5b202486826, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=刚刚结束的ESMO会议，盘点下结直肠癌海报专场的8个研究！, objectType=article, longId=180715, objectId=d5a0180e1534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a0180e1534, replyNumber=0, likeNumber=76, createdTime=2020-04-21, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a0180e1534, moduleTitle=刚刚结束的ESMO会议，盘点下结直肠癌海报专场的8个研究！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5a0180e1534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024840, encodeId=58f0202484088, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, objectType=article, longId=174987, objectId=88ee1e49876f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ee1e49876f, replyNumber=0, likeNumber=78, createdTime=2019-07-27, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ee1e49876f, moduleTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ee1e49876f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024873, encodeId=0d8320248e374, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=【2019 ESMO】卵巢癌一线治疗研究, objectType=article, longId=181069, objectId=f3a018106972, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3a018106972, replyNumber=0, likeNumber=72, createdTime=2020-04-21, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3a018106972, moduleTitle=【2019 ESMO】卵巢癌一线治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3a018106972)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024876, encodeId=b58820248e683, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019 ESMO：奥希替尼治疗EGFR exon 20ins突变NSCLC再添新证, objectType=article, longId=181109, objectId=276b18110977, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=276b18110977, replyNumber=0, likeNumber=72, createdTime=2020-01-21, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=276b18110977, moduleTitle=2019 ESMO：奥希替尼治疗EGFR exon 20ins突变NSCLC再添新证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=276b18110977)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024854, encodeId=c9ba202485475, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS, objectType=article, longId=180458, objectId=cfa118045850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfa118045850, replyNumber=0, likeNumber=67, createdTime=2020-02-08, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfa118045850, moduleTitle=“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfa118045850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024869, encodeId=13c62024869fa, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, objectType=article, longId=180793, objectId=fd6a180e93a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd6a180e93a8, replyNumber=0, likeNumber=70, createdTime=2020-05-06, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd6a180e93a8, moduleTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd6a180e93a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024856, encodeId=846d2024856b0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗, objectType=article, longId=180460, objectId=b398180460d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b398180460d6, replyNumber=0, likeNumber=84, createdTime=2020-05-22, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b398180460d6, moduleTitle=2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b398180460d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024844, encodeId=970b20248441d, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期, objectType=article, longId=175278, objectId=115d1e52785c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=115d1e52785c, replyNumber=0, likeNumber=62, createdTime=2019-10-06, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=115d1e52785c, moduleTitle=2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=115d1e52785c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024859, encodeId=62252024859c3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, objectType=article, longId=180568, objectId=34561805686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34561805686b, replyNumber=0, likeNumber=52, createdTime=2020-04-22, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34561805686b, moduleTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34561805686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024867, encodeId=207d202486eae, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移, objectType=article, longId=180697, objectId=623d18069eb4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623d18069eb4, replyNumber=0, likeNumber=66, createdTime=2020-03-12, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623d18069eb4, moduleTitle=2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623d18069eb4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024853, encodeId=994b202485345, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念, objectType=article, longId=180454, objectId=2c23180454c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c23180454c6, replyNumber=0, likeNumber=74, createdTime=2020-04-06, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c23180454c6, moduleTitle=2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c23180454c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024857, encodeId=7c64202485e51, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO：肺癌脑转移的预测提供新的探索途径, objectType=article, longId=180463, objectId=a9c91804639f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9c91804639f, replyNumber=0, likeNumber=78, createdTime=2019-12-01, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9c91804639f, moduleTitle=ESMO：肺癌脑转移的预测提供新的探索途径, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9c91804639f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024852, encodeId=6c0120248524a, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019 ESMO|辅助到晚期一线治疗，同样需对肾细胞癌患者进行精细化的分层管理, objectType=article, longId=180453, objectId=3c7b180453c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c7b180453c1, replyNumber=0, likeNumber=65, createdTime=2020-06-21, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c7b180453c1, moduleTitle=2019 ESMO|辅助到晚期一线治疗，同样需对肾细胞癌患者进行精细化的分层管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c7b180453c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024841, encodeId=4ac8202484174, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用, objectType=article, longId=175018, objectId=a1a91e501898, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1a91e501898, replyNumber=0, likeNumber=78, createdTime=2019-11-19, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1a91e501898, moduleTitle=2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1a91e501898)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024836, encodeId=c685202483641, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Breast：间歇性治疗降低晚期乳腺癌患者的治疗效果, objectType=article, longId=165497, objectId=74b916549e94, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74b916549e94, replyNumber=0, likeNumber=90, createdTime=2019-08-12, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74b916549e94, moduleTitle=ESMO Breast：间歇性治疗降低晚期乳腺癌患者的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74b916549e94)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024855, encodeId=edc5202485563, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓, objectType=article, longId=180459, objectId=8e4a1804599f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e4a1804599f, replyNumber=0, likeNumber=69, createdTime=2019-11-26, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e4a1804599f, moduleTitle=【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e4a1804599f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SMO

2020-05-29

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO-WCGI大会主席说：肿瘤患者的抗凝治疗不应忽视

2020-05-19

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO世界胃肠癌大会：murlentamab的II期临床研究结果

2019-10-19

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新

2020-05-20

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效

2020-02-18

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

刚刚结束的ESMO会议，盘点下结直肠癌海报专场的8个研究！

2020-04-21

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究

2019-07-27

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

【2019 ESMO】卵巢癌一线治疗研究

2020-04-21

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019 ESMO：奥希替尼治疗EGFR exon 20ins突变NSCLC再添新证

2020-01-21

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

“氟维司群+”频频亮相ESMO, MONARCH-2研究再证氟维司群联合治疗改善OS

2020-02-08

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好

2020-05-06

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗

2020-05-22

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期

2019-10-06

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期

2020-04-22

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移

2020-03-12

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念

2020-04-06

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO：肺癌脑转移的预测提供新的探索途径

2019-12-01

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019 ESMO|辅助到晚期一线治疗，同样需对肾细胞癌患者进行精细化的分层管理

2020-06-21

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用

2019-11-19

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Breast：间歇性治疗降低晚期乳腺癌患者的治疗效果

2019-08-12

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓

2019-11-26

科室
- - 订阅+
  - 更多科室
工具
服务